Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 5.42%1.29T | 5.08%5.26T | 2.58%1.48T | 1.49%1.24T | 3.64%1.32T | 14.29%1.22T | 11.77%5T | 11.04%1.44T | 17.53%1.23T | 18.65%1.27T |
Cost of revenue | 5.34%913.59B | 3.21%3.71T | 2.95%1.04T | -0.59%866.53B | -0.02%934.15B | 11.69%867.27B | 11.97%3.6T | 6.90%1.01T | 16.36%871.7B | 21.98%934.38B |
Gross profit | 5.63%372.9B | 9.88%1.55T | 1.69%431.39B | 6.62%377.41B | 13.80%384.02B | 21.21%353.03B | 11.26%1.41T | 22.35%424.23B | 20.50%353.97B | 10.31%337.46B |
Operating expense | 7.61%314.24B | 6.36%1.22T | 0.03%325.2B | 7.25%290.91B | 6.28%309.19B | 13.50%292.02B | 13.04%1.14T | 14.13%325.1B | 12.36%271.25B | 15.97%290.92B |
Selling and administrative expenses | 8.80%316.07B | 7.77%1.24T | 7.05%345.11B | 6.34%292.12B | 6.15%309.47B | 12.01%290.5B | 13.25%1.15T | 14.11%322.38B | 13.38%274.69B | 16.13%291.55B |
-General and administrative expense | 8.80%316.07B | 7.77%1.24T | 7.05%345.11B | 6.34%292.12B | 6.15%309.47B | 12.01%290.5B | 13.25%1.15T | 14.11%322.38B | 13.38%274.69B | 16.13%291.55B |
Other operating expenses | -220.24%-1.83B | -481.20%-19.88B | -831.52%-19.91B | 65.00%-1.21B | 54.95%-282M | 173.42%1.52B | -189.10%-3.42B | 16.23%2.72B | -297.58%-3.44B | -232.98%-626M |
Operating profit | -3.85%58.66B | 25.22%328.53B | 7.13%106.19B | 4.56%86.49B | 60.80%74.83B | 79.61%61.01B | 4.09%262.35B | 60.24%99.13B | 57.99%82.72B | -15.48%46.54B |
Net non-operating interest income (expenses) | 37.93%11.86B | 18.82%9.51B | 1,892.17%3.89B | -49.23%-4B | -67.34%1.02B | 10.67%8.6B | -13.05%8.01B | -104.97%-217M | -193.09%-2.68B | 555.23%3.13B |
Non-operating interest income | 43.74%14.15B | 72.33%21.2B | 296.18%6.01B | 29.06%5.34B | 8.85%4.39B | 15.83%9.84B | 3.29%12.3B | -66.09%1.52B | 18.31%4.14B | 376.60%4.03B |
Non-operating interest expense | 83.91%2.29B | 172.04%11.69B | 22.32%2.12B | 36.99%9.34B | 274.00%3.37B | 70.98%1.24B | 58.99%4.3B | 1,520.56%1.73B | 1,002.75%6.82B | -41.33%900M |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | -23.01%5.61B | 27.47%27.82B | 60.73%6.75B | 13.95%6.74B | 7.64%7.05B | 41.06%7.28B | 18.37%21.82B | -32.62%4.2B | 64.33%5.92B | 45.19%6.55B |
Special income (charges) | ||||||||||
Other non-operating income (expenses) | ||||||||||
Income before tax | -0.99%76.13B | 25.22%365.85B | 13.31%116.83B | 3.81%89.24B | 47.47%82.9B | 63.95%76.88B | 4.46%292.18B | 42.30%103.11B | 46.10%85.96B | -4.53%56.22B |
Income tax | 42.01%21.75B | 2.49%68.91B | -36.05%16.3B | 10.22%21.09B | 42.40%16.2B | 36.35%15.32B | 8.78%67.24B | 79.98%25.49B | 45.24%19.14B | -5.68%11.38B |
Net income | -11.68%54.37B | 32.01%296.95B | 29.52%100.53B | 1.98%68.15B | 48.76%66.7B | 72.64%61.57B | 3.24%224.94B | 33.14%77.62B | 46.34%66.82B | -4.23%44.84B |
Net income continuous operations | -11.68%54.37B | 32.01%296.95B | 29.52%100.53B | 1.98%68.15B | 48.76%66.7B | 72.64%61.57B | 3.24%224.94B | 33.14%77.62B | 46.34%66.82B | -4.23%44.84B |
Noncontrolling interests | 40.22%5.24B | 8.70%12B | -45.09%1.68B | -1.26%2.28B | 22.90%4.31B | 71.99%3.73B | -23.38%11.04B | -6.92%3.05B | 13.38%2.31B | -8.22%3.51B |
Net income attributable to the company | -15.04%49.14B | 33.21%284.95B | 32.57%98.85B | 2.09%65.87B | 50.95%62.39B | 72.68%57.83B | 5.12%213.91B | 35.53%74.57B | 47.88%64.52B | -3.88%41.33B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -15.04%49.14B | 33.21%284.95B | 32.57%98.85B | 2.09%65.87B | 50.95%62.39B | 72.68%57.83B | 5.12%213.91B | 35.53%74.57B | 47.88%64.52B | -3.88%41.33B |
Gross dividend payment | ||||||||||
Basic earnings per share | -14.16%23.53 | 34.00%135.74 | 33.72%47.23 | 2.88%31.44 | 51.61%29.67 | 72.82%27.41 | 6.17%101.3 | 36.00%35.32 | 49.22%30.56 | -2.59%19.57 |
Diluted earnings per share | -14.16%23.53 | 34.00%135.74 | 33.72%47.23 | 2.88%31.44 | 51.61%29.67 | 72.82%27.41 | 6.17%101.3 | 36.00%35.32 | 49.22%30.56 | -2.59%19.57 |
Dividend per share | 0 | 25.00%50 | 15.38%30 | 0 | 42.86%20 | 0 | 0.00%40 | 0.00%26 | 0 | 0.00%14 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |